Treatment

New subgroup data from the phase 3 ROSELLA trial show that adding relacorilant (Lifyorli) to nab-paclitaxel significantly improves survival for patients with platinum-resistant ovarian cancer, regardless of prior taxane treatment history. With a median follow-up of 24.8 months, patients receiving the combination therapy achieved a median overall survival of 16.0 months, compared with 11.9 months […]

Updated results from the RUBY phase 3 trial suggest that adding the immunotherapy drug dostarlimab to standard chemotherapy may offer the potential for long-term cure in patients with advanced or recurrent dMMR/MSI-H endometrial cancer. After a median follow-up of 55.6 months, patients receiving dostarlimab plus carboplatin and paclitaxel achieved a 4-year progression-free survival rate of

B7-H3 is emerging as one of the most promising targets in cancer therapy because it is highly expressed across many solid tumors while remaining limited in normal tissues. Several antibody-drug conjugates (ADCs) targeting B7-H3 are now showing encouraging early results in lung, prostate, and gynecologic cancers. In small cell lung cancer, Ifinatamab deruxtecan received FDA

Daraxonrasib (RMC-6236), an investigational RAS(ON) inhibitor, is generating major attention in metastatic pancreatic ductal adenocarcinoma (PDAC) after positive Phase 3 RASolute 302 trial results showed significant improvements in overall survival and progression-free survival compared with standard chemotherapy. The drug has received FDA breakthrough therapy and orphan drug designations for previously treated metastatic PDAC. The results

The Phase 3 HERIZON-GEA-01 trial showed that zanidatamab-hrii (Ziihera)-based regimens significantly improved outcomes for patients with previously untreated HER2-positive advanced gastric, gastroesophageal junction, and esophageal cancers. The study enrolled 914 patients who received either zanidatamab plus tislelizumab and chemotherapy, zanidatamab plus chemotherapy, or standard trastuzumab plus chemotherapy. At a median follow-up of 25.9 months, both

A new post hoc analysis of the phase 3 TALAPRO-2 trial found that radiographic progression-free survival (rPFS) strongly correlates with overall survival (OS) in first-line metastatic castration-resistant prostate cancer (mCRPC). The analysis evaluated patients treated with Talazoparib plus Enzalutamide or enzalutamide alone and showed consistent moderate-to-strong correlations across all major patient groups. The strongest association

The Phase 3 RECITE trial found that romiplostim can help gastrointestinal cancer patients stay on full-dose chemotherapy by preventing chemotherapy-induced thrombocytopenia (CIT), a condition marked by dangerously low platelet counts. The international study included 165 patients, most with stage 4 colorectal cancer receiving oxaliplatin-based chemotherapy. Researchers reported that 84% of patients treated with romiplostim avoided

An updated analysis showed that the telomerase inhibitor Imetelstat significantly improves survival in patients with high-risk myelofibrosis whose disease relapsed or became resistant after JAK inhibitor treatment. Researchers compared 59 IMbark patients with a matched real-world group of 54 patients treated before 2016. After nearly four years of follow-up, median overall survival reached 30.7 months

A roundtable discussion led by Thomas Hutson highlighted the growing role of adjuvant Pembrolizumab in high-risk clear cell renal cell carcinoma (ccRCC) following nephrectomy, based on results from the phase 3 KEYNOTE-564 trial. The study compared one year of pembrolizumab versus placebo in patients with resected high-risk disease and showed a 29% reduction in recurrence

Ten-year follow-up data from the phase 2 NCT01500733 trial showed that continuous treatment with Ibrutinib provides long-term disease control for patients with high-risk chronic lymphocytic leukemia (CLL), including those with TP53 abnormalities. Among 84 patients, median progression-free survival reached 7.2 years, while median overall survival was not yet reached. The 10-year progression-free survival rate was